BICRAL

Summary

BICRAL (BICRA like chromatin remodeling complex associated protein, HGNC:21111) is a protein-coding gene on chromosome 6p21.1, encoding BRD4-interacting chromatin-remodeling complex-associated protein-like (Q6AI39). Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner.

Predicted to be involved in positive regulation of DNA-templated transcription. Part of SWI/SNF complex.

Source: NCBI Gene 23506 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 154 total
• MANE Select transcript: NM_001393499

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21111
Approved symbol	BICRAL
Name	BICRA like chromatin remodeling complex associated protein
Location	6p21.1
Locus type	gene with protein product
Status	Approved
Aliases	SMARCK2
Ensembl gene	ENSG00000112624
Ensembl biotype	protein_coding
OMIM	618502
Entrez	23506

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000314073, ENST00000394168, ENST00000909955, ENST00000924106, ENST00000924108, ENST00000924110, ENST00000954760

RefSeq mRNA: 3 — MANE Select: NM_001393499 NM_001318819, NM_001393499, NM_015349

CCDS: CCDS34451

Canonical transcript exons

ENST00000314073 — 13 exons

Exon	Start	End
ENSE00001252281	42864659	42868556
ENSE00001458870	42810306	42810401
ENSE00001517658	42782052	42782101
ENSE00004012570	42855856	42855917
ENSE00004012571	42860262	42860356
ENSE00004012572	42822796	42822844
ENSE00004012573	42862510	42862612
ENSE00004012574	42828493	42830172
ENSE00004012575	42822018	42822063
ENSE00004012576	42853638	42853738
ENSE00004012577	42822935	42823003
ENSE00004012578	42857091	42857236
ENSE00004012579	42852092	42852197

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 93.50.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.2145 / max 98.6419, expressed in 1732 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
67821	2.0729	787
67812	2.0670	1023
67819	1.2820	631
67818	1.1244	714
67814	1.0568	432
67820	0.4383	269
67813	0.1732	78

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cerebellar vermis	UBERON:0004720	93.50	gold quality
urethra	UBERON:0000057	93.03	gold quality
mammary duct	UBERON:0001765	92.31	gold quality
epithelium of mammary gland	UBERON:0003244	92.31	gold quality
endothelial cell	CL:0000115	91.86	gold quality
saphenous vein	UBERON:0007318	91.67	gold quality
penis	UBERON:0000989	91.20	gold quality
trigeminal ganglion	UBERON:0001675	90.86	gold quality
buccal mucosa cell	CL:0002336	90.70	gold quality
pylorus	UBERON:0001166	90.33	gold quality
synovial joint	UBERON:0002217	90.18	gold quality
medial globus pallidus	UBERON:0002477	90.05	gold quality
renal medulla	UBERON:0000362	89.93	gold quality
nipple	UBERON:0002030	89.92	gold quality
inferior vagus X ganglion	UBERON:0005363	89.77	gold quality
pancreatic ductal cell	CL:0002079	89.66	gold quality
globus pallidus	UBERON:0001875	89.64	gold quality
superior surface of tongue	UBERON:0007371	89.59	gold quality
subthalamic nucleus	UBERON:0001906	89.33	gold quality
cauda epididymis	UBERON:0004360	89.29	gold quality
dorsal root ganglion	UBERON:0000044	89.23	gold quality
ventral tegmental area	UBERON:0002691	89.04	gold quality
superior vestibular nucleus	UBERON:0007227	89.02	gold quality
trabecular bone tissue	UBERON:0002483	88.89	gold quality
paraflocculus	UBERON:0005351	88.77	gold quality
cardia of stomach	UBERON:0001162	88.75	gold quality
caput epididymis	UBERON:0004358	88.49	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	88.43	gold quality
substantia nigra pars compacta	UBERON:0001965	88.25	gold quality
seminal vesicle	UBERON:0000998	88.15	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.11
E-GEOD-109979	no	49.73

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

150 targeting BICRAL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-12133	99.92	71.82	2006

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	bicral	ENSDARG00000016089
mus_musculus	Bicral	ENSMUSG00000036568
rattus_norvegicus	Bicral	ENSRNOG00000016229

Paralogs (1): BICRA (ENSG00000063169)

Protein

Protein identifiers

BRD4-interacting chromatin-remodeling complex-associated protein-like — Q6AI39 (reviewed: Q6AI39)

Alternative names: Glioma tumor suppressor candidate region gene 1 protein-like

All UniProt accessions (1): Q6AI39

UniProt curated annotations — full annotation on UniProt →

Function. Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner.

Subunit / interactions. Component of the multiprotein chromatin-remodeling complexes SWI/SNF: SWI/SNF-A (BAF), SWI/SNF-B (PBAF) and related complexes. The canonical complex contains a catalytic subunit (either SMARCA4/BRG1/BAF190A or SMARCA2/BRM/BAF190B) and at least SMARCE1, ACTL6A/BAF53, SMARCC1/BAF155, SMARCC2/BAF170, and SMARCB1/SNF5/BAF47. Other subunits specific to each of the complexes may also be present permitting several possible combinations developmentally and tissue specific. Component of the SWI/SNF (GBAF) subcomplex, which includes at least BICRA or BICRAL (mutually exclusive), BRD9, SS18, the core BAF subunits, SMARCA2/BRM, SMARCA4/BRG1/BAF190A, ACTL6A/BAF53, SMARCC1/BAF155, and SMARCD1/BAF60A.

RefSeq proteins (3): NP_001305748, NP_001380428, NP_056164 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR015671	GSCR1_dom	Domain
IPR052438	Chromatin_remod/trans_coact	Family

Pfam: PF15249

UniProt features (15 total): region of interest 5, compositionally biased region 5, modified residue 2, sequence conflict 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6AI39-F1	46.40	0.07

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 623, 980

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9933947	Formation of the non-canonical BAF (ncBAF) complex

MSigDB gene sets: 162 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, BROWNE_HCMV_INFECTION_6HR_DN, BROWNE_HCMV_INFECTION_48HR_DN, CATTTCA_MIR203, CCTGTGA_MIR513, GOBP_MAINTENANCE_OF_CELL_NUMBER, GOBP_REGULATION_OF_STEM_CELL_POPULATION_MAINTENANCE, TTGGAGA_MIR5155P_MIR519E, TCCAGAT_MIR5165P, GOBP_NEGATIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, GOBP_POSITIVE_REGULATION_OF_DEVELOPMENTAL_PROCESS, CTTTGTA_MIR524, GOBP_CHROMATIN_REMODELING, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN

GO Biological Process (6): chromatin remodeling (GO:0006338), regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of cell population proliferation (GO:0008284), negative regulation of cell differentiation (GO:0045596), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of stem cell population maintenance (GO:1902459)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (4): chromatin (GO:0000785), nucleoplasm (GO:0005654), SWI/SNF complex (GO:0016514), GBAF complex (GO:0140288)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
SWI/SNF chromatin remodelers	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
cellular anatomical structure	2
SWI/SNF superfamily-type complex	2
chromatin organization	1
transcription by RNA polymerase II	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell differentiation	1
regulation of cell differentiation	1
negative regulation of cellular process	1
negative regulation of developmental process	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
stem cell population maintenance	1
positive regulation of developmental process	1
positive regulation of multicellular organismal process	1
regulation of stem cell population maintenance	1
binding	1
chromosome	1
nuclear lumen	1

Protein interactions and networks

STRING

1040 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
BICRAL	BRD9	Q9H8M2	983
BICRAL	BICRA	Q9NZM4	754
BICRAL	SMARCD1	Q96GM5	750
BICRAL	DPF1	Q92782	744
BICRAL	SMARCC1	Q92922	740
BICRAL	BCL7C	Q8WUZ0	670
BICRAL	BCL7B	Q9BQE9	666
BICRAL	SMARCA4	P51532	665
BICRAL	ACTL6A	O96019	654
BICRAL	BRD7	Q9NPI1	632
BICRAL	PHF10	Q8WUB8	614
BICRAL	ARID2	Q68CP9	607
BICRAL	DPF2	Q92785	604
BICRAL	PBRM1	Q86U86	602
BICRAL	SMARCE1	Q969G3	553

IntAct

82 interactions, top by confidence:

A	B	Type	Score
SMARCD1	ARID1A	psi-mi:“MI:0914”(association)	0.790
BCL7A	ARID1A	psi-mi:“MI:0914”(association)	0.640
BCL7C	ARID1A	psi-mi:“MI:0914”(association)	0.640
FNDC3B	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	ARHGDIG	psi-mi:“MI:0915”(physical association)	0.560
SS18L1	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
PRR20D	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
ATXN1	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
QRICH1	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
TRIM23	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
HSPB2	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	USHBP1	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	DTX2	psi-mi:“MI:0915”(physical association)	0.560
NRF1	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	BANP	psi-mi:“MI:0915”(physical association)	0.560
HGS	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
BFSP2	BICRAL	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	NGLY1	psi-mi:“MI:0915”(physical association)	0.560
BICRAL	EXOC8	psi-mi:“MI:0915”(physical association)	0.560
SS18L2	ARID1A	psi-mi:“MI:2364”(proximity)	0.480
SS18L2	ARID1A	psi-mi:“MI:0914”(association)	0.480
CACHD1	BICRAL	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (55): GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-MS), GLTSCR1L (Affinity Capture-RNA), SMARCA4 (Affinity Capture-Western), BRD9 (Affinity Capture-Western), ACTL6A (Affinity Capture-Western), GLTSCR1L (Affinity Capture-Western), GLTSCR1L (Two-hybrid), GLTSCR1L (Two-hybrid), GLTSCR1L (Two-hybrid), TRIM23 (Two-hybrid)

ESM2 similar proteins: A0A0R4IBL7, A3RK74, A4L7N3, A5D7F6, B2RWS6, B5DE09, E1BPQ1, G3V7R4, O00512, O43524, P11420, P45481, P78364, Q09472, Q12778, Q13227, Q14686, Q15596, Q17BA4, Q61026, Q64028, Q66JJ0, Q67FY2, Q6AI39, Q6JHU9, Q6T264, Q7ZUK7, Q810W5, Q86UU0, Q8CHH5, Q8CHP6, Q8IXK0, Q8IZL2, Q921N8, Q924H2, Q92585, Q92793, Q961D9, Q96JK9, Q96RN5

Diamond homologs: F8VPZ9, Q6AI39, Q8CHH5, Q9NZM4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 35 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of the canonical BAF (cBAF) complex	6	190.3×	8e-12
Formation of the non-canonical BAF (ncBAF) complex	5	167.9×	1e-09
Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF)	7	159.9×	5e-13
Formation of the embryonic stem cell BAF (esBAF) complex	5	150.3×	2e-09
Regulation of MITF-M-dependent genes involved in pigmentation	7	93.0×	1e-11
Regulation of endogenous retroelements	5	92.1×	2e-08
MITF-M-dependent gene expression	5	45.3×	5e-07
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	7	41.2×	2e-09

GO biological processes:

GO term	Partners	Fold	FDR
regulation of G0 to G1 transition	6	168.5×	1e-10
regulation of nucleotide-excision repair	6	150.5×	2e-10
regulation of mitotic metaphase/anaphase transition	6	123.9×	4e-10
positive regulation of double-strand break repair	6	86.0×	3e-09
regulation of G1/S transition of mitotic cell cycle	6	76.6×	5e-09
chromatin remodeling	6	18.2×	2e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

154 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	137
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2311 predictions. Top by Δscore:

Variant	Effect	Δscore
6:42822012:TTATA:T	acceptor_loss	1.0000
6:42822013:TATAG:T	acceptor_loss	1.0000
6:42822014:ATAG:A	acceptor_loss	1.0000
6:42822015:T:G	acceptor_gain	1.0000
6:42822015:TAGT:T	acceptor_loss	1.0000
6:42822016:A:AG	acceptor_gain	1.0000
6:42822016:AG:A	acceptor_loss	1.0000
6:42822017:G:GT	acceptor_gain	1.0000
6:42822017:GT:G	acceptor_gain	1.0000
6:42822017:GTT:G	acceptor_gain	1.0000
6:42822062:GG:G	donor_gain	1.0000
6:42822063:GG:G	donor_gain	1.0000
6:42822064:G:GA	donor_loss	1.0000
6:42822064:G:GG	donor_gain	1.0000
6:42822065:TAAGA:T	donor_loss	1.0000
6:42822790:TTCTA:T	acceptor_loss	1.0000
6:42822792:CTA:C	acceptor_loss	1.0000
6:42822794:A:AC	acceptor_loss	1.0000
6:42822794:A:AG	acceptor_gain	1.0000
6:42822795:G:GG	acceptor_gain	1.0000
6:42822795:GA:G	acceptor_gain	1.0000
6:42822840:AATCT:A	donor_gain	1.0000
6:42822841:ATCT:A	donor_gain	1.0000
6:42822843:CT:C	donor_gain	1.0000
6:42822843:CTG:C	donor_loss	1.0000
6:42822845:G:GG	donor_gain	1.0000
6:42822845:GTAA:G	donor_loss	1.0000
6:42822846:TAA:T	donor_loss	1.0000
6:42822847:AA:A	donor_loss	1.0000
6:42822933:A:AG	acceptor_gain	1.0000

AlphaMissense

7120 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:42828650:T:A	L106H	1.000
6:42828650:T:C	L106P	1.000
6:42828662:T:C	L110S	1.000
6:42828670:G:C	A113P	1.000
6:42860319:T:C	L771P	1.000
6:42860337:T:C	L777P	1.000
6:42860340:T:C	L778P	1.000
6:42828658:T:C	S109P	0.999
6:42828659:C:T	S109F	0.999
6:42828677:T:A	I115N	0.999
6:42828677:T:C	I115T	0.999
6:42828677:T:G	I115S	0.999
6:42828692:T:C	L120S	0.999
6:42857180:T:C	L733P	0.999
6:42860273:T:C	F756L	0.999
6:42860275:T:A	F756L	0.999
6:42860275:T:G	F756L	0.999
6:42860285:G:C	A760P	0.999
6:42860286:C:A	A760D	0.999
6:42860295:T:C	L763P	0.999
6:42860298:T:C	L764P	0.999
6:42860327:T:C	Y774H	0.999
6:42860327:T:G	Y774D	0.999
6:42860351:G:C	A782P	0.999
6:42862548:G:C	R796S	0.999
6:42862548:G:T	R796S	0.999
6:42862553:T:C	F798S	0.999
6:42865420:G:C	A1072P	0.999
6:42865436:T:C	L1077P	0.999
6:42822810:T:C	L19S	0.998

dbSNP variants (sampled 300 via entrez): RS1000032114 (6:42761050 A>G,T), RS1000038181 (6:42855127 C>T), RS1000050543 (6:42769688 A>C,G), RS1000087928 (6:42820826 G>A), RS1000151262 (6:42810535 G>T), RS1000151475 (6:42767483 G>T), RS1000165223 (6:42852661 C>A), RS1000173734 (6:42765864 G>A), RS1000180130 (6:42816955 A>G), RS1000184877 (6:42785231 G>C), RS1000218466 (6:42809968 G>A), RS1000222672 (6:42836171 T>C), RS1000252810 (6:42791185 C>G), RS1000308556 (6:42861663 C>T), RS1000335663 (6:42779966 C>T)

Disease associations

OMIM: gene MIM:618502 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), autism spectrum disorder (MONDO:0005258)

Orphanet (2): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010002_324	Refractive error	2.000000e-12

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	5
Benzo(a)pyrene	affects methylation, decreases expression, increases mutagenesis	4
Arsenic	increases abundance, increases methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	increases expression	1
bisphenol A	affects cotreatment, increases methylation	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression, increases abundance	1
butyraldehyde	decreases expression	1
benzo(e)pyrene	increases methylation	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Resveratrol	affects cotreatment, decreases expression, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Leflunomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Atrazine	decreases expression	1
Caffeine	decreases phosphorylation	1
Carbamazepine	affects expression	1
Cisplatin	decreases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methapyrilene	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer